Abstract
Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 million cases per year reported in India. AD and other kinds of dementia are more common as individuals become older, affecting 1 in every 14 people over the age of 65 and 1 in every 6 people over the age of 80. ADUHELM (Aducanumab) is a monoclonal antibody, new class of medication needed for treatment of AD. The latest drug used to treat underlying cause of AD and recent studies shown to be efficacious and safe for the AD. Our review emphasizes on the drug information of Aducanumab and its clinical importance in AD.
Highlights
Onset Alzheimer disease (EOAD) is a neurodegenerative dementing disorder that is relatively rare (
presenilin 2 (PSEN2) mutations are reported to be associated with Alzheimer’s disease (AD) of both early onset and variable age onset as well as with other neurodegenerative disorders such as Lewy Body dementia, frontotemporal dementia, Parkinson dementia, and posterior cortical atrophy[2,3,4].; Patients most often present with an insidious loss of episodic memory followed by a slowly progressive dementia that evolves over years.[3]
Apolipoprotein E epsilon 4, presenilin 1 and presenilin 2 are four genes that have been linked to hereditary vulnerability to AD
Summary
Onset Alzheimer disease (EOAD) is a neurodegenerative dementing disorder that is relatively rare (
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
